Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vera Therapeutics, Inc. (VERA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
17.03+0.57 (+3.46%)
At close: 04:00PM EDT
17.09 +0.06 (+0.35%)
After hours: 04:05PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.46
Open16.84
Bid6.79 x 800
Ask17.09 x 2200
Day's Range16.32 - 17.63
52 Week Range13.01 - 37.11
Volume63,739
Avg. Volume96,653
Market Cap362.358M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.83
  • GlobeNewswire

    Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

    Atacicept is the first known investigational therapy to decrease both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies which correlate with increased risk of IgA nephropathy disease progressionNew analysis shows atacicept improved renal function in patients with mild-to-moderate renal disease in Phase 2 study of atacicept in systemic lupus erythematosusBRISBANE, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on devel

  • GlobeNewswire

    Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

    Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022, following positive clinical strategy meeting with FDA earlier this year Results from a 12-week interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned in June 2022; Phase 2b or Phase 3 clinical trial of MAU868 expected to initiate in 2023Strong balance sheet with approximately $151 million

  • GlobeNewswire

    Vera Therapeutics to Present at Upcoming Conferences in May 2022

    BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at the following conferences in May, as detailed below: LifeSci Partners Immunology & Inflammation Symposium (May 10 – 11, 2022) Format:Fireside ChatDate

Advertisement
Advertisement